Full history for every metric is available with a Kvantra account
Avanos Medical, Inc. (AVNS)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 715 | 745 | 684 | 673 | 688 | 701 | 716 |
| Operating profit | $m | -62 | -57 | |||||
| Net profit | $m | -27 | 6 | 51 | -62 | -392 | -68 | -69 |
| EPS reported | $ | -1.46 | -1.50 | |||||
| Operating cashflow per share | $ | 1.61 | 0.79 | |||||
| Capex per share | $ | 0.68 | 0.63 | |||||
| FCF per share | $ | 0.93 | 0.16 | |||||
| Free cash flow | $m | 43 | 8 | |||||
| Net debt | $m | 11 | 33 | |||||
| Book value equity | $m | 778 | 782 | |||||
| Book value per share | $ | 16.77 | 16.86 | |||||
| Number of shares | m | 46.4 | 46.4 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.67 | 1.50 | |||||
| P/S LTM | x | 0.74 | 1.64 | |||||
| P/FCF LTM | x | 12.09 | 156.10 | |||||
| EV/EBITDA LTM | x | -16.88 | -55.71 | |||||
| EV/Sales LTM | x | 0.80 | 1.68 | |||||
| Earnings Yield LTM | % | -13.03% | -5.99% | |||||
| FCF Yield | % | 8.27% | 0.64% | |||||
| Quality | ||||||||
| ROE | % | -8.73% | -8.91% | |||||
| ROIC | % | -6.65% | -6.03% | |||||
| Operating margin | % | -8.78% | -7.92% | |||||
| Gross margin | % | 49.77% | 48.55% | |||||
| FCF/Sales | % | 6.15% | 1.05% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +1.95% | +3.87% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | -48.01% | -93.42% | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | 0.33 | 0.05 | |||||
| Net Debt/EBITDA | x | -1.18 | -3.37 | |||||
| EBIT/Net interest | x | -15.40 | -7.88 | |||||
| Net debt/market cap | % | 2.05% | 2.78% | |||||
| Net debt/Equity | x | 0.01 | 0.04 | |||||
| Gross debt/equity | x | 0.17 | 0.18 | |||||
Company overview
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Avanos Medical, Inc. (AVNS)
Avanos Medical, Inc. is a pioneering medical technology enterprise dedicated to furnishing device solutions across a broad international footprint, encompassing North America, Europe, the Middle East, Africa, the Asia Pacific region, and Latin America. Its comprehensive product array targets two primary areas: chronic care and non-opioid pain management. Within chronic care, the company provides digestive health offerings such as Mic-Key enteral feeding tubes, Corpak patient feeding systems, and NeoMed solutions tailored for neonatal and pediatric patients. Its respiratory health segment includes closed airway suction systems and other airway management devices, marketed under prominent brands like Ballard, Microcuff, and Endoclear. For non-opioid pain relief, Avanos offers acute pain solutions, including On-Q and ambIT surgical pain pumps, along with Game Ready cold and compression therapy systems. It also features interventional pain solutions, providing minimally invasive therapies like Coolief for long-term pain alleviation. The company facilitates product access by selling directly to hospitals, various healthcare providers, and end-user facilities, in addition to utilizing third-party wholesale distributors. Originally incorporated in 2014 and known as Halyard Health, Inc., the company officially adopted the name Avanos Medical, Inc. in June 2018 and maintains its headquarters in Alpharetta, Georgia.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free